Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CART-19 and 20 cells
- Development stage
- Preclinical
- Lead developer
- Henan Cancer Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
**CART-19 and 20 cells** is an investigational dual-target chimeric antigen receptor T-cell therapy developed by Henan Cancer Hospital for relapsed or refractory CD19-positive/CD20-positive B-cell non-Hodgkin lymphoma. The product is designed to direct engineered T cells against both CD19 and CD20 on malignant B cells, promoting CAR-mediated T-cell activation and cytotoxic elimination of antigen-expressing lymphoma cells. It is being evaluated following cyclophosphamide and fludarabine lymphodepleting preconditioning in the registered single-group clinical study NCT06160362. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06160362))
- Other names
- CD19/CD20 chimeric antigen receptor T cellsdouble-target CART-19 and 20 cells
02
Targets
Beyond the preview
Go deeper on CART-19 and 20 cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CART-19 and 20 cells.